Product Description
Epinephrine is one of the most commonly used agents in various settings as it functions as medication and hormone. It is currently FDA-approved for various situations, including emergency treatment of type 1 hypersensitivity reactions, including anaphylaxis, induction, and maintenance of mydriasis during intraocular surgeries and hypotension due to septic shock. It also has several off-label uses. Epinephrine is a sympathomimetic catecholamine that exerts its pharmacologic effects on both alpha and beta-adrenergic receptors using a G protein-linked second messenger system. It has a greater affinity for beta receptors in small doses. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK482160/)
Mechanisms of Action: ADRB Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Inhalant,Nasal,Intramuscular
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Anaphylaxis | Anaphylaxis | Anaphylaxis | Anaphylaxis | Mydriasis | Hypotension | Shock, Septic | Anaphylaxis | Shock, Septic | Hypotension | Shock, Septic | Anastesia Related
Known Adverse Events: Dizziness | Headache | Tremor | Pallor | Ventricular Fibrillation | Parkinson Disease | Hyperthyroidism | Anaphylaxis | General Diabetes | Pheochromocytoma | Mydriasis | Cerebral Hemorrhage | Common Cold | Pain Unspecified
Company: Amphastar
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China, Israel, Japan, Sweden
Active Clinical Trial Count: 7
Highest Development Phases
Phase 3: Anaphylaxis|Cardiac Arrest
Phase 1: Communicable Diseases|Respiratory Tract Infections|Rhinitis, Allergic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2022-500137-89-00 | P3 |
Unknown Status |
Cardiac Arrest |
2025-02-27 |
|
| NP-006-Epinephrine | P2 |
Completed |
Anaphylaxis |
2024-02-02 |
49% |
| DMC-CL-002 | P1 |
Completed |
Anaphylaxis |
2023-12-15 |
|
| CTR20230407 | P1 |
Completed |
Rhinitis, Allergic |
2023-05-05 |